- Mustang Bio Inc MBIO has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).
- The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.
- MB-106 is a CD20-targeted, autologous CAR T cell therapy.
- Related: Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial.
- In addition, the Office for Human Research Protections has approved Federalwide Assurance for Mustang's research for the protection of human subjects in research.
- Price Action: MBIO shares are up 3.98% at $2.32 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
